Amundi’s Arbutus Biopharma ABUS Stock Holding History

Amundi’s Portfolio ABUS Stock Details ABUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$53.5K	Hold	11,878	–	–	﹤0.01%	1979
2025 Q4	$57.1K	Buy	+11,878	New	+$53.4K	﹤0.01%	1827

Other funds holding ABUS

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

TSC

Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return

WCM

Whitefort Capital Management New York $339M AUM 52.48% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Amundi's ABUS Position: Q1 2026 in Review

Amundi held its Arbutus Biopharma (ABUS) position steady in Q1 2026 at 11,878 shares worth $53.5K. The position accounts for ﹤0.01% of the portfolio, ranked #1979.

Amundi first reported a position in ABUS in Q4 2025 and has held it in 2 quarters since. The position peaked at $57.1K in Q4 2025. 167 funds tracked by Wall St. Rank hold ABUS as of Q1 2026.

Amundi held 11,878 shares of Arbutus Biopharma worth $53.5K as of Q1 2026.
Amundi left its Arbutus Biopharma share count unchanged in Q1 2026.
Arbutus Biopharma made up ﹤0.01% of Amundi's portfolio in Q1 2026, its #1979 holding.
Amundi first reported a position in Arbutus Biopharma in Q4 2025 and has held it in 2 quarters since.
Amundi's Arbutus Biopharma position peaked at $57.1K in Q4 2025.
167 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q1 2026.

Based on Amundi's 13F filing for Q1 2026, filed 18 May 2026.